A head-to-head comparison of Medtronic’s (NYSE:MDT) Resolute stent and Abbott’s (NYSE:ABT) market-leading Xience V DES showed "non-inferiority" between the two, according to results from the Twente study presented last week at the Transcatheter Cardiovascular Therapeutics symposium.
Boston Scientific
GPOs: Premier and Cure Surgicals ink new supply deals
Group purchasing organization goliath Premier inked two new agreements for electrophysiology equipment and Cure Surgicals signed a supply deal for surgical aspirators and bone cutters.
Premier healthcare alliance signed agreements with C.R. Bard (NYSE:BCR) subsidiary Bard Electrophysiology Products and Natick, Mass.-based Boston Scientific (NYSE:BSX).
Olympus shares rise on abated de-listing threat | MassDevice.com Wall Street Beat
Shares of Olympus Corp. (TYO:7733) regained more than 17 percent over the weekend after the Tokyo stock exchange indicated it might not de-list the world’s largest endoscope maker, brought low by a scheme to hide its losses with buyouts.
GE Healthcare begins PMA process for 3D breast scanner | Regulatory Roundup
GE Healthcare (NYSE:GE) filed the first module of its pre-market approval application for the breast tomosynthesis option of its Senographe Essential system.
The health care giant said the first submission included a device description and non-clinical information, including "phantom testing," and detector performance evaluation. The system is intended as an add-on option for the Senographe Essential to produce 3D images for screening and diagnosis of breast cancer.
TCT 2011: Three ways to spur U.S. medical innovation
The U.S. medical device arena is in danger of ceding the throne to countries with friendlier regulatory environments but the system is not irreparable, Dr. Martin Leon said during a lecture at this week’s Transcatheter Cardiovascular Therapeutics symposium in San Francisco.
Baxter CEO Parkinson cashes in, reaps $14 million | Wall Street Beat
Robert Parkinson Jr., chairman & CEO of Baxter International (NYSE:BAX), added 20 percent to his paycheck total from last year by cashing in on stock options for the first time.
Parkinson, 60, who earned $11.5 million last year, netted $14.1 million last month after exercising the options and selling stock.
TCT 2011: Medtronic, Boston Scientific, Abbott continue the Stent Wars
AngioDynamics adds two to executive team | Personnel Moves
AngioDynamics (NSDQ:ANGO) added two new VPs to its executive team.
The Albany, N.Y.-based device maker named Matthew Kapusta senior VP of business development and Donna Haire senior VP of regulatory, quality, clinical and medical affairs.
MDT CEO nixes spine spinout, FDA labeling, BSX COO, Stryker’s court case, Artificial pancreas, Airport scanners, KCI’s $6.3B BO | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Abbott wins FDA nod for Xience Prime stent
Can thinner stents handle the pressure?
Next-generation stents with thinner profiles and increased flexibility may not be as strong as their thicker forbears, according to researchers.
Thinner stents may have lower longitudinal strength or compressibility, an aspect of stent engineering that hasn’t traditionally held much significance in design.